MDK and prostate cancer: For instance, siRNA targeting midkine (a tumor promoting factor, MDK) (iMDK) (53) induces cell cycle arrest at the S and G2/M phases, decreases p-Akt levels, and significantly up-regulates PTEN expression in CD133-positive population of prostate cancer cells (53).